Journal ArticleDOI
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Laurent Kodjikian,Laurent Kodjikian,Eric H. Souied,G. Mimoun,G. Mimoun,Martine Mauget-Faÿsse,Francine Behar-Cohen,Evelyne Decullier,Laure Huot,Gilles Aulagner +9 more
Reads0
Chats0
TLDR
Bvacizumab was noninferior to ranibizumAB for visual acuity at 1 year with similar safety profiles, and Ranibizuab tended to have a better anatomic outcome.Citations
More filters
Journal ArticleDOI
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire,Daniel F. Martin,Gui-Shuang Ying,Glenn J. Jaffe,Ebenezer Daniel,Juan E. Grunwald,Cynthia A. Toth,Frederick L. Ferris,Stuart L. Fine +8 more
TL;DR: Vision gains during the first 2 years were not maintained, but 50% of eyes had VA of 20/40 or better, confirming anti-vascular endothelial growth factor therapy as a major long-term therapeutic advance for neovascular AMD.
Journal ArticleDOI
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth,Victor Chong,Anat Loewenstein,Michael Larsen,Eric H Souied,Reinier O. Schlingemann,Bora Eldem,Jordi Monés,Gisbert Richard,Francesco Bandello +9 more
TL;DR: Ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up, but definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management.
Journal ArticleDOI
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).
Ursula Schmidt-Erfurth,José García-Arumí,Francesco Bandello,Karina Berg,Usha Chakravarthy,Bianca S. Gerendas,Jost B. Jonas,Michael Larsen,Ramin Tadayoni,Anat Loewenstein +9 more
TL;DR: As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema, and anti-vascular endothelial growth factor therapy has emerged as first-line therapy and Steroids have maintained a role in the management of chronically persistent DME.
Journal ArticleDOI
Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration
Sharon D. Solomon,Kristina Lindsley,S. Swaroop Vedula,Magdalena G. Krzystolik,Barbara S. Hawkins +4 more
TL;DR: When compared with control treatments, participants who received any of the three anti-VEGF agents were more likely to have gained 15 letters or more of visual acuity, lost fewer than 15 letters of visual Acuity, and had vision 20/200 or better after one year of follow up.
Journal ArticleDOI
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
TL;DR: Bvaczumab and ranibizumab had equivalent effects on visual acuity at 1 year when administered according to a treat-and-extend protocol, and the visual acute results were comparable to those of other clinical trials with monthly treatment.
References
More filters
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F. Martin,Maureen G. Maguire,Gui-Shuang Ying,Juan E. Grunwald,Stuart L. Fine,Glenn J. Jaffe +5 more
TL;DR: Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizuab administered monthly, although the comparison between bevacizumAB as needed and monthly bevicizumabs was inconclusive.
Journal ArticleDOI
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.
TL;DR: An updated extension of the CONSORT checklist for reporting noninferiority and equivalence trials is presented, based on the 2010 version of theconsORT Statement and the 2008 CONSORT Statement for the reporting of abstracts, and illustrative examples and explanations for those items that differ from the main 2010consORT checklist are provided.
Related Papers (5)
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more